---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-005802"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2024-02-28T23:59:59+00:00"
generated_at: "2026-06-05T07:52:29.506840+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics reports Q4 2023 BRIUMVI net revenue $39.9M; 2024 target $220-260M

## Summary
- BRIUMVI U.S. net revenue $39.9M in Q4 2023, $88.8M for full year 2023.
- Net loss of $14.4M in Q4; net income of $12.7M for full year 2023.
- Year-end cash $217.5M; 2024 BRIUMVI net revenue target $220-260M; operating expense ~$250M.
- License revenue $141.7M in 2023 driven by $140M Neuraxpharm payment for ex-U.S. rights.
- Pipeline: subcutaneous BRIUMVI, azer-cel CAR T in autoimmune disease to start trials in 2024.

## SEC filing metadata
- accession: 0001437749-24-005802
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2024-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/0001437749-24-005802-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/tgtx20240227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-005802
- JSON: https://secwatch.observer/filing/0001437749-24-005802.json
- Plain text: https://secwatch.observer/filing/0001437749-24-005802.txt

## Key facts
- Earnings Releases
  TG THERAPEUTICS, INC. updated its the fourth quarter and year ended December 31, 2023 guidance (raised).
  - Period: the fourth quarter and year ended December 31, 2023
  - Guidance: raised
  - Result: reported results
  source text: On February 28, 2024, TG Therapeutics, Inc. (the “Company”) issued a press release announcing results of operations for the three and twelve months ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1001316/000143774924005802/0001437749-24-005802-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.